Posted by Michael Wonder on 23 Dec 2025
Viridian Therapeutics announces BLA acceptance and priority review for veligrotug for the treatment of thyroid eye disease
22 December 2025 - PDUFA target action date of 30 June 2026.
Viridian Therapeutics today announced that the US FDA has accepted the biologics license application for veligrotug for the treatment of thyroid eye disease.
